American Association for Cancer Research
10780432ccr191431-sup-221572_2_supp_5970274_q2jpjj.docx (117.18 kB)

Figure S1 from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Download (117.18 kB)
journal contribution
posted on 2023-03-31, 21:05 authored by Ravi Vij, Rajneesh Nath, Daniel E.H. Afar, María-Victoria Mateos, Jesús G. Berdeja, Marc S. Raab, Andreas Guenther, Joaquín Martínez-López, Andrzej J. Jakubowiak, Xavier Leleu, Katja Weisel, Shekman Wong, Scott Gulbranson, James P. Sheridan, Anita Reddy, Bruno Paiva, Anil Singhal, Jesús F. San-Miguel, Philippe Moreau

Study design schematic. N, number of patients in each dose group; PK/PD, pharmacokinetics/pharmacodynamics.



ABBV-838 is an antibody–drug conjugate targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells. This phase I/Ib first-in-human, dose-escalation study (trial registration ID: NCT02462525) evaluated the safety, pharmacokinetics, and preliminary activity of ABBV-838 in patients with relapsed and refractory multiple myeloma (RRMM). Eligible patients (≥18 years) received ABBV-838 (3+3 design) intravenously starting from 0.6 mg/kg up to 6.0 mg/kg for 3-week dosing intervals (Q3W). Patients could continue ABBV-838 for up to 24 months. Assessment of alternate dosing intervals (Q1W and Q2W) was conducted in parallel. As of March 2017, 75 patients received at least one dose of ABBV-838. The most common any-grade treatment-emergent adverse events (TEAE) were neutropenia and anemia (28.0% each), fatigue (26.7%), and nausea (25.3%). Grade 3/4/5 TEAEs were reported in 73.3% of patients across all treatment groups; most common were neutropenia (20.0%), anemia (18.7%), and leukopenia (13.3%). Grade 3/4/5 ABBV-838–related TEAEs were reported by 40.0% of patients across all treatment groups. Overall, 4.0% of patients experienced TEAEs leading to death, none ABBV-838 related. The MTD was not reached; the selected recommended dose for the expansion cohort was 5.0 mg/kg Q3W. Pharmacokinetic analysis showed that exposure was approximately dose proportional. The overall response rate was 10.7%; very good partial responses and partial responses were achieved by 2 (2.7%) and 6 (8.0%) patients, respectively. These results demonstrate that ABBV-838 is safe and well-tolerated in patients with RRMM with a very limited efficacy.

Usage metrics

    Clinical Cancer Research



    Ref. manager